|Videos|March 1, 2022

Improvements in bone-metastasis-related pain and QoL demonstrated in mCRPC with Lutetium-177 PSMA-617

“Those that did complete the surveys generally reported average improvements in bone-metastasis-related pain and ability to function despite that pain,” says Brian D. Gonzalez, PhD.

In this video, Brian D. Gonzalez, PhD, discusses the background, findings, and takeaways of the study, “Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gonzalez is an associate member and quality of life researcher at Moffitt Cancer Center in Tampa, Florida.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME